Ausgabe 1/2018
Inhalt (21 Artikel)
AN-7, a butyric acid prodrug, sensitizes cutaneous T-cell lymphoma cell lines to doxorubicin via inhibition of DNA double strand breaks repair
- PRECLINICAL STUDIES
Lilach Moyal, Neta Goldfeiz, Batia Gorovitz, Ada Rephaeli, Efrat Tal, Nataly Tarasenko, Abraham Nudelman, Yael Ziv, Emmilia Hodak
CUDC-907, a dual HDAC and PI3K inhibitor, reverses platinum drug resistance
- PRECLINICAL STUDIES
Kenneth K. W. To, Li-wu Fu
Crucial microRNAs and genes in metformin’s anti-pancreatic cancer effect explored by microRNA-mRNA integrated analysis
- PRECLINICAL STUDIES
Yilong Li, Le Li, Guangquan Zhang, Yongwei Wang, Hua Chen, Rui Kong, Shangha Pan, Bei Sun
The kinesin Eg5 inhibitor K858 induces apoptosis and reverses the malignant invasive phenotype in human glioblastoma cells
- PRECLINICAL STUDIES
Ludovica Taglieri, Giovanna Rubinacci, Anna Giuffrida, Simone Carradori, Susanna Scarpa
A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors
- PHASE I STUDIES
Janice M. Mehnert, Gerald Edelman, Mark Stein, Heather Camisa, Joanne Lager, Jean-François Dedieu, Anne-Frédérique Ghuysen, Jyoti Sharma, Li Liu, Patricia M. LoRusso
Phase I study of Nedaplatin, a platinum based antineoplastic drug, combined with nab-paclitaxel in patients with advanced squamous non–small cell lung cancer
- PHASE I STUDIES
Satoshi Igawa, Sakiko Otani, Yoshiro Nakahara, Shinichiro Ryuge, Yasuhiro Hiyoshi, Tomoya Fukui, Hisashi Mitsufuji, Masaru Kubota, Masato Katagiri, Yuichi Sato, Jiichiro Sasaki, Noriyuki Masuda
A phase Ib study of everolimus combined with metformin for patients with advanced cancer
- Open Access
- PHASE I STUDIES
Remco J. Molenaar, Tim van de Venne, Mariëtte J. Weterman, Ron A. Mathot, Heinz-Josef Klümpen, Dick J. Richel, Johanna W. Wilmink
Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials
- PHASE I STUDIES
Jean-Marie Michot, Lina Benajiba, Laura Faivre, Capucine Baldini, Lelia Haddag, Clement Bonnet, Christophe Massard, Frederic Bigot, Camille Bigenwald, Benjamin Verret, Zoé A. P. Thomas, Andrea Varga, Anas Gazzah, Antoine Hollebecque, David Ghez, Julien Lazarovici, Rastilav Balheda, Aurore Jeanson, Sophie Postel-Vinay, Alina Danu, Jean-Charles Soria, Xavier Paoletti, Vincent Ribrag
A Phase I study to determine safety, pharmacokinetics, and pharmacodynamics of ANF-RHO™, a novel PEGylated granulocyte colony-stimulating factor, in healthy volunteers
- PHASE I STUDIES
Hemant Misra, John Berryman, Ronald Jubin, Abraham Abuchowski
Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors
- PHASE I STUDIES
Glen J. Weiss, Gayle Jameson, Daniel D. Von Hoff, Barbara Valsasina, Cristina Davite, Claudia Di Giulio, Francesco Fiorentini, Rachele Alzani, Patrizia Carpinelli, Alessandro Di Sanzo, Arturo Galvani, Antonella Isacchi, Ramesh K. Ramanathan
Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
- PHASE II STUDIES
Glen J. Weiss, Lisa Blaydorn, Julia Beck, Kirsten Bornemann-Kolatzki, Howard Urnovitz, Ekkhard Schütz, Vivek Khemka
A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma
- PHASE II STUDIES
Sandra P. D’Angelo, Omid A. Hamid, Ahmad Tarhini, Dirk Schadendorf, Bartosz Chmielowski, Frances A. Collichio, Anna C. Pavlick, Karl D. Lewis, Susan C. Weil, John Heyburn, Charles Schweizer, Daniel J. O’Shannessy, Richard D. Carvajal
Phase II study of doxorubicin and thalidomide in patients with refractory aggressive fibromatosis
- PHASE II STUDIES
Xin Liu, Huijie Wang, Xianghua Wu, Xiaonan Hong, Zhiguo Luo
Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads
- REVIEW
Joanna C. Masters, Dana J. Nickens, Dawei Xuan, Ronald L. Shazer, Michael Amantea
Ganoderic acid, lanostanoid triterpene: a key player in apoptosis
- REVIEW
Balraj Singh Gill, Navgeet, Richa Mehra, Vicky Kumar, Sanjeev Kumar
A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event
- SHORT REPORT
Francesco Gelsomino, Giovanni Vitale, Andrea Ardizzoni
Chemotherapy-induced cardiomyopathy caused by Pemetrexed
- SHORT REPORT
Takuya Oyakawa, Kei Iida, Masatoshi Kusuhara, Hirotsugu Kenmotsu, Takashi Sugino
Feasibility of olanzapine, multi acting receptor targeted antipsychotic agent, for the prevention of emesis caused by continuous cisplatin- or ifosfamide-based chemotherapy
- SHORT REPORT
Seiko Bun, Kan Yonemori, Toru Akagi, Emi Noguchi, Tatsunori Shimoi, Akihiko Shimomura, Mayu Yunokawa, Chikako Shimizu, Yasuhiro Fujiwara, Yoshinori Makino, Yoshikazu Hayashi, Kenji Tamura
Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers
- SHORT REPORT
Marie Bréchon, Marie Dior, Johann Dréanic, Bertrand Brieau, Marie-Anne Guillaumot, Catherine Brezault, Olivier Mir, François Goldwasser, Romain Coriat
Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing
- SHORT REPORT
Kyoungmin Lee, Changhoon Yoo, Kyu-pyo Kim, Kyoung-Jin Park, Heung-Moon Chang, Tae Won Kim, Jae-Lyun Lee, Woochang Lee, Sang Soo Lee, Do Hyun Park, Tae Jun Song, Dong Wan Seo, Sung Koo Lee, Myung-Hwan Kim, Sang Hyun Shin, Dae Wook Hwang, Ki Byung Song, Jae Hoon Lee, Song Cheol Kim, Baek-Yeol Ryoo
Acknowledgement of Reviewers 2017
- ACKNOWLEDGEMENTS